Study of Pregabalin (an Approved Drug) For the Treatment of Pain Associated with PHN, Conducted at Several Clinical Sites Where all Patients Enrolled Receive Pregabalin

Mise à jour : Il y a 5 ans
Référence : EUCTR2011-005972-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to obtain pilot prospective data to explore whether sensory symptom cluster analysis is useful for predicting treatment response in PHN. - Phenotype PHN subjects entering study with sensory symptom clustering using the PainPREDICT, PainDETECT and NPSI questionnaires, “baseline pain interference with sleep”, Patient Health Questionnaire 8 (PHQ-8), Generalized Anxiety Disorder 7-item (GAD-7), as well as Pain Catastrophizing Scale (PCS) questionnaire. - Find “responders” and “non-responders” to treatment (pregabalin). - Compare distribution of phenotypes within “responder” and “non-responder” groups.


Critère d'inclusion

  • Postherpetic Neuralgia (PHN)